Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
向80亿美元的德国市场进行轻资产扩张增加了纳斯达克这只大麻股票的潜力
The potential rescheduling of cannabis in the U.S. and the growing demand in Germany positions InterCure (NASDAQ:INCR), the leading seller of pharmaceutical cannabis outside North America, to capitalize on these opportunities, according to a recent initiation note by Pablo Zuanic of Zuanic & Associates.
根据Zuanic & Associates的Pablo Zuanic最近发布的启动报告，美国可能重新安排大麻的期限以及德国需求的增长，使北美以外主要的药用大麻销售商InterCure（纳斯达克股票代码：INCR）有能力抓住这些机会。
Zuanic highlighted said that "InterCure's experience in Israel, a market five years ahead of Germany in development, gives it a competitive edge." He also noted that "down the road, INCR could enter the U.S. market if FDA-approved and controlled pharmaceutical cannabis is federally legalized. In a global industry context, InterCure has...
祖安尼奇强调说：“InterCure在以色列的市场发展比德国领先五年，其经验使其具有竞争优势。”他还指出，“...
登录免费看全文
登录/注册